Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31688426 | 0.79 | KDM4E (0.51) | ATMKDM4ELMNAPOLBKDM1A | |
| SCHEMBL30404708 | 0.78 | SIRT2 (0.39) | ATMPOLBKDM1ARCOR1 | |
| SCHEMBL3699321 | 0.76 | — | — | |
| SCHEMBL28486442 | 0.74 | HDAC3 (0.49) | ATMKDM4ELMNAPOLBHDAC3 | |
| SCHEMBL5204640 | 0.74 | — | — | |
| SCHEMBL1951692 | 0.74 | ATM (0.40) | ATMKDM4ELMNAPOLBKCNMA1 | |
| Hydrochloric Acid SCHEMBL8592377 | 0.74 | KDM4E (0.41) | ATMKDM4ELMNAPOLBKDM1A | |
| SCHEMBL1193629 | 0.73 | — | — | |
| SCHEMBL30350 | 0.73 | — | — | |
| SCHEMBL6782595 | 0.73 | TSHR (0.50) | ATMKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559564-B2 | Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition and antibody-mediated target cytosis | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| CN-121378090-A | Guanidine carbonyl pyrrole-based functionalized amphiphilic resorcinol calixarene and nanoparticle containing same | 南京航空航天大学 | 2026-01-23 | — | — | CN | disclosed |
| US-20250289903-A1 | METHODS AND COMPOSITIONS FOR TREATING EOSINOPHIL DRIVEN DISEASES AND DISORDERS | Purinomia Biotech, Inc. | 2025-09-18 | — | — | US | disclosed |
| US-20250270293-A1 | SCAFFOLD PROTEINS | AVACTA LIFE SCIENCES LIMITED (GB) | 2025-08-28 | — | — | US | disclosed |
| WO-2025122385-A1 | METHODS AND COMPOSITIONS FOR REDUCING SCAR FORMATION AND TREATING DERMATOLOGICAL WOUNDS | Purinomia Biotech, Inc. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-12286468-B2 | Scaffold proteins | AVACTA LIFE SCIENCES LIMITED (GB) | 2025-04-29 | — | — | US | disclosed |
| CN-114127121-B | Methods and compositions for promoting and enhancing T cell mediated immune responses through ADCC targeting of CD39 expressing cells | 北京恩瑞尼生物科技股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-4514389-A1 | METHODS AND COMPOSITIONS FOR TREATING EOSINOPHIL DRIVEN DISEASES AND DISORDERS | Purinomia Biotech, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20250059294-A1 | METHODS AND COMPOSITIONS FOR PROMOTING AND POTENTIATING T-CELL MEDIATED IMMUNE RESPONSES THROUGH ADCC TARGETING OF CD39 EXPRESSING CELLS | Purinomia Biotech, Inc. | 2025-02-20 | — | — | US | disclosed |
| CN-119409834-A | Methods and compositions for promoting and enhancing T cell mediated immune responses through ADCC targeting of CD39 expressing cells | 北京恩瑞尼生物科技股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20170283810-A1 | Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2403859-B1 | MOLECULAR TWEEZERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV CALIFORNIA (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2576522-B1 | ZN (II) BASED COLORIMETRIC SENSOR AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-8791092-B2 | Molecular tweezers for the treatment of amyloid-related diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130130306-A1 | ZN (II) BASED COLORIMETRIC SENSOR AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-05-23 | — | — | US | disclosed |
| EP-2576522-A1 | ZN (II) BASED COLORIMETRIC SENSOR AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2013-04-10 | — | — | EP | disclosed |
| US-20120108548-A1 | MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2403859-A2 | MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | The Regents of the University of California (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011151683-A1 | ZN (II) BASED COLORIMETRIC SENSOR AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-12-08 | — | — | WO | disclosed |
| WO-2010102248-A2 | MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270293-A1 | SCAFFOLD PROTEINS | TRIM28, PHAX, KPNA1 | ATM 3160/4885KDM4E 2276/4885LMNA 1074/4885 |
| US-12559564-B2 | Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition and antibody-mediated target cytosis | ENTPD1, FCGR2A, FCGR1A | ATM 3448/4885KDM4E 656/4885LMNA 3511/4885 |
| US-20170283810-A1 | Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof | CD4, CD74, HLA-DRB1 | ATM 3239/4885KDM4E 4706/4885LMNA 2142/4885 |
| US-12286468-B2 | Scaffold proteins | TRIM28, PHAX, KPNA1 | ATM 3160/4885KDM4E 2276/4885LMNA 1074/4885 |
| US-20250059294-A1 | METHODS AND COMPOSITIONS FOR PROMOTING AND POTENTIATING T-CELL MEDIATED IMMUNE RESPONSES THROUGH ADCC TARGETING OF CD39 EXPRESSING CELLS | CD209, ENTPD1, ENTPD3 | ATM 1132/4885KDM4E 1343/4885LMNA 4556/4885 |
| US-20120108548-A1 | MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | ATM 2075/4885KDM4E 264/4885LMNA 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.